Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
i RECIST A guideline for data management and
i RECIST A guideline for data management and
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
Assessing Immunotherapy Response and Progression
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
iRECIST Overview
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Kaplan-Meier curves of OS and PFS based on iRECIST to compare outcomes... | Download Scientific Diagram
EPOS™
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Rationale Grows for the Immune-Related Response Criteria
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
Criteria of Assessment with Imaging iRECIST, irRECIST, irRC, RECIST1.1
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
iRECIST
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST | Journal of Clinical Oncology
